IP Library Granted Patent US 9,724,353
Granted Patent B2
US 9,724,353 · App. 14/512,608 · Granted Aug 8, 2017

Methods for treating intrapulmonary infections

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,724,353
App. No.
14/512,608
Granted
Aug 8, 2017
Kind
B2
Abstract

This disclosure relates to the treatment of intrapulmonary bacterial infections, including treatment of nosocomial pneumonia lung infections with pharmaceutical compositions containing the cephalosporin ceftolozane.

Claims (13)

1. A method of treating an infection selected from the group consisting of: nosocomial pneumonia, ventilator acquired pneumonia and hospital acquired pneumonia, the method comprising repeatedly intravenously administering 2.0 g of ceftolozane and 1.0 g of tazobactam to a subject in need thereof about once every 8 hours.

2. The method of claim 1 , wherein the method comprises administering the ceftolozane as a 60-minute infusion.

3. The method of claim 1 , wherein the ceftolozane is a hydrogen sulfate salt.

4. The method of claim 1 , wherein the ceftolozane and tazobactam are administered as a single pharmaceutical composition.

5. The method of claim 4 , wherein the method comprises administering the pharmaceutical composition as a 60-minute infusion.

6. The method of claim 1 , wherein the pneumonia is nosocomial pneumonia.

7. The method of claim 1 , wherein the pneumonia is ventilator acquired pneumonia.

8. The method of claim 1 , wherein the pneumonia is hospital acquired pneumonia.

9. The method of claim 1 , wherein the ceftolozane is administered in its free base form.

10. The method of claim 1 , wherein the ceftolozane is administered in its salt form.

11. The method of claim 6 , wherein the ceftolozane is administered in its free base form.

12. The method of claim 6 , wherein the ceftolozane is administered in its salt form.

13. The method of claim 1 , wherein the infection comprises one or more pathogens selected from the group consisting of: Pseudomonas aeruginosa, E. coli and K. pneumoniae.

Assignments (4)
MERGER Recorded Aug 8, 2022
From: MERCK SHARP & DOHME CORP.
To: MERCK SHARP & DOHME LLC
Reel/Frame 061102/0145 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 19, 2017
From: PARSONS, TARA; CHANDORKAR, GURUDATT A.; UMEH, OBIAMIWE C.; HUNTINGTON, JENNIFER A.
To: CUBIST PHARMACEUTICALS, INC.
Reel/Frame 042436/0011 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 19, 2017
From: CUBIST PHARMACEUTICALS LLC
To: CALIXA THERAPEUTICS, INC
Reel/Frame 042436/0202 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 3, 2015
From: CALIXA THERAPEUTICS, INC.
To: MERCK SHARP & DOHME CORP.
Reel/Frame 037198/0658 →